Tue, Jul 22, 2014, 6:11 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

RXi Pharmaceuticals Corporation Message Board

  • auburndale303 auburndale303 Dec 4, 2013 10:51 AM Flag

    In Play

    OCLS receives FDA clearance for Microcyn scar management hydro gel. Targeting 2nd gtr 2014.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • OCLS is at $6+ from $2 yesterday, on 4,000,000 shares in the first hour and a half today.

      It is a gel that is used to reduce scarring. What is so much better about RXII, that prevents scarring, and a gel that reduces it substantially later?

      I am not asking the above rhetorically? The figure of $5,000,000,000 has been used a lot here as the annual sales potential for RXII's sales. NEVER have I seen anything about its competition such as OCLS, its price and whether or not it would be competitive, or its probable need.

      My point: Sure RXII seems to #$%$ scarring but what does that really mean in a vacuum where we do not consider alternative palliatives, price of the various alternatives vs. RXII, or need.

      How about some discussion on those matters? Do we really have the potential of a triple in one day with RXII, or has OCLS a taken a lot of the potential away?

      So helpme_hanna

      P.S. I am long RXII but am beginning to think there is less there than meets the eye.

    • $OCLS is complete #$%$, but enjoy the trading if that's your thing.

    • rxi-109 decreases scarring during the wound healing process or through scar revision surgery by up to 50%. It is not a topical cream as Oculus' treatment which claims to reduce an existing scar.

      There are many topical compounds that claim to diminish a scar. RXI limits the scarring at the outset in planned surgeries......................good luck All

 
RXII
2.49+0.01(+0.40%)Jul 22 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.